Tampa Bay Business Journal – July 11
Moffitt Cancer Center produces most of Tampa’s clinical research, having accounted for 27 percent of it in 2018. The area’s largest academic health system, University of South Florida Health, produced 12.8 percent of the research last year, while Florida Cancer Specialists and Research Institute produced 6.9 percent, BayCare Health Systems produced 6 percent and Tampa General Hospital produced 5.8 percent of the area’s output.
Gulf Breeze News – July 11
On June 7, the former newspaper writer, editor, personal chef and cookbook author underwent a pancreatectomy at Moffitt Cancer Center in Tampa.
Tampa Bay Reporter – July 11
She serves as chair of the Hospital Board of H. Lee Moffitt Cancer Center and Research and vice chair of its Institute (Parent) Board.
Health News Digest – July 10
According to Robert Gatenby, M.D., co-founder and director of Moffitt’s Center of Excellence for Evolutionary Therapy, the optimal result of treatment for metastatic cancers, in evolutionary terms, is extinction of the cancer population.
Cancer Therapy Advisor – July 10
“I was impressed by these results, because mesothelin-targeted trials have been tested before and the results have been a little underwhelming, so the fact we can see a clinical response in this case with minimal toxicity, this is remarkable,” said Daniel Abate-Daga, PhD, assistant member of the department of immunology at Moffit Cancer Center and assistant professor in the department of oncological sciences at the University of South Florida, Tampa.
Latino Leaders – July 10
- Lee Moffitt Cancer Center and Research Institute: As one of the leading cancer research and treatment facilities in the nation, the Tampa, Florida-based hospital is also serving one of the most diverse populations.
Cancer Network - July 10
Roger Li, MD, a genitourinary oncologist with the Moffitt Cancer Center in Tampa, Florida, said this study is limited by its small sample size. He noted that there is a lot of homogeneity in patients with UTUC and LTUC and sampling errors are difficult to overcome in bulk sequencing studies.
PR Web – July 9
Forte’s leadership and product innovation teams regularly meet with its Customer Advisory Board (CAB), in which Moffitt Cancer Center & Research Institute, Cedars-Sinai Medical Center and others take part.
Tampa Bay Newspapers – July 10
Powell-Stafford launched her career at Yale New Haven Hospital and later worked for the Moffitt Cancer Center in Tampa. She first joined the HCA ranks in 2008, when she was hired as the assistant administrator at Community Hospital in New Port Richey.
eCancer News – July 9
Moffitt researchers, in collaboration with scientists from the UF Health Cancer Center and Sylvester Comprehensive Cancer Center, wanted to determine how this resistance develops and identify additional drugs that could be used in combination with MEK inhibitors to target uveal melanoma cells for destruction.
OncLive – July 9
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.
Targeted Oncology – July 8
Nikhil I. Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the rationale for combining nivolumab (Opdivo) with bempegaldesleukin (NKTR-214) for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.
OncLive – July 8
Participating today on our distinguished panel are: Dr Rami Komrokji, senior member and professor of oncologic sciences, section head for leukemia and myelodysplastic syndromes [MDS], and vice chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida.
Fort Myers News-Press – July 7
In addition Gambrel-Irizarry will head to Moffitt Cancer Center in Tampa on Monday for a possible lumpectomy. She beat breast cancer once before but needs to be checked for a possible recurrence.
Tampa Bay Times – July 7
As the program has grown, Decker and Ford have worked on unique cases over the years with doctors at Moffitt Cancer Center, Johns Hopkins All Children's Hospital, St. Joseph's Hospital and even with veterinarians at Busch Gardens and the Florida Aquarium. They’ve even 3-D printed the skull of a baby sloth and the leg of a penguin.
MedCity News – July 5
Dr. Richard Kim, a gastrointestinal cancer specialist at the Moffitt Cancer Center in Tampa, Florida, also noted that it was tough to draw any conclusions from such a small number of patients. “But the trial just demonstrated that it is feasible to combine it with chemo,” he wrote in an email.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.